RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Daviddal, I think the R+D collaboration with Servier ends next month (as opposed to Dec '07). As you said, the existing license agreement for ex-US Neurodegenerative and Anxiety continues on, but since S-18986 isn't covered under that agreement, it will have to be updated for Servier to eventually commercialize S-18986.

BTW, I think the enrollment for the S-18986 MCI study was boosted up from 450 to a whopping 500 patients. All I could think of was that they're probably expecting a ton of dropouts, since they dose for a full 12 months (!) I sense another potential disaster in the making, but hopefully they'll still get some useful data. As a benzothiadiazine, S-18986 is probably fairly neurotrophic, but it may have its share of side effects, so one might have expected AD to be a more appropriate target indication. As we saw with the CX-516 MCI study, MCI patients don't tolerate side effects very well at all (and with 12 months of daily dosing, good luck..)

I assume that the compounds that have been jointly developed by Servier and Cortex under the R+D collaboration still fall under the existing/ongoing licensing agreement. I remember several years ago there was an announcement about one jointly developed compound in particular which was 2000 times more potent than CX-516, and neurotrophic. I always assumed it was from Cortex's benzamide family of compounds, since Cortex was involved with its development. Wonder what ever happened to that one? Of course Cortex's new approach is for ultra short acting high impacts, so perhaps that "monster" compound was just too powerful.